Stryker (SYK) is back in focus after a March 2026 cyberattack disrupted operations and contributed to missed first quarter revenue and earnings expectations, even as management reiterated full year guidance and recovery plans.

The share price has pulled back to $294.23, with a 30 day share price return of 11.4% and a year to date share price return showing a 15.49% decline. The 5 year total shareholder return of 25.01% contrasts with the weaker 1 year total shareholder return of 22.33%. This suggests that momentum has faded after the cyberattack and first quarter earnings miss.

If this kind of reset in sentiment has you reassessing healthcare exposure, it could be a good moment to scan for other medical technology and healthcare AI opportunities using the 35 healthcare AI stocks.

With Stryker trading at $294.23, a 19.49% intrinsic discount and a 32.31% gap to analyst targets frame a clear question: is the recent weakness a chance to buy, or is the market already pricing in future growth?

Most Popular Narrative: 9.1% Undervalued

According to a widely followed narrative by Tokyo, a fair value of $323.52 sits above the last close at $294.23, which puts the recent pullback in a different light.

Stryker has a solid balance sheet, I always want to see more equity than debt, which is the case with $19.2b (equity) versus $12.9b (debt) and leads to a debt to equity ratio of 67%. If we even take the cash position into account, which is $2.4b, the debt may be reduced to $10.5b, and we end up with a net debt to equity ratio of 54%.

Curious how a company with meaningful debt, growing earnings and a projected step up in free cash flow still lands as undervalued in this narrative? The answer sits in the mix of cash flow, profitability and return on equity assumptions that support that $323.52 fair value and may surprise anyone only looking at recent share price weakness.

Result: Fair Value of $323.52 (UNDERVALUED)

However, there are still clear risks that could derail this undervalued case, including any prolonged impact from the cyberattack or weaker than expected free cash flow delivery.

Another View: Higher P/E, Higher Expectations

While the DCF based narrative points to undervaluation, the P/E ratio tells a more demanding story. Stryker trades at 33.8x earnings compared with 23.9x for the US Medical Equipment industry and 30.9x for peers, which is above an estimated fair ratio of 30.5x.

That richer multiple suggests the market already prices in a lot of good news. This raises the bar for future delivery and leaves less room for disappointment if growth or margins soften.

Next Steps

With sentiment clearly divided between risks and rewards, this is a moment to look through the data yourself and decide where you stand quickly. To help frame both sides of the argument, start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

Before you move on, use this moment of reflection on Stryker to line up a few fresh ideas that could round out your watchlist and spark your next move.

• Spot potential value opportunities early by scanning the screener containing 23 high quality undiscovered gems that combine strong fundamentals with relatively low market attention.
• Prioritise quality and stability by checking the solid balance sheet and fundamentals stocks screener (44 results) if you want companies with sturdy finances at the core of your portfolio.
• Lock in your income focus by reviewing the 12 dividend fortresses and see which higher yield stocks might deserve a closer look before they move out of reach.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.